NCT07814586Not yet recruiting
Prognostic Evaluation and Systematic Re-Assessment of Cholangiocarcinoma Therapy
The Re-ACT Study: Prognostic Evaluation and Systematic Re-Assessment of Chol- Angiocarcinoma Therapy
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
Prospective observational cohort study including patients with a diagnosis of intrahepatic/perihilar cholangiocarcinoma at the central regional multidisciplinary conference, to assess therapy response, patient-reported quality of life, patient-reported symptoms/experiences and biomarkers. For patients diagnosed with localized unresectable disease, the study will document the multidisciplinary re-assessment of therapy response.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 2 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2029
- Lead sponsor
- Karolinska University Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07814586
What you commit to
- Study type: Observational
- Planned participants: 900
- From Sept 2026 to the primary completion date, Sept 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18 years
Who the study is looking for
- Clinical diagnosis of intrahepatic- or perihilar cholangiocarcinoma at the regional multidisciplinary team conference
- For inclusion in the re-assessment arm, a diagnosis of localized, unresectable cholangiocarcinoma at the regional multidisciplinary team conference and clinically evaluated as candidate for tumor-directed medical therapy
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.